[The leuko-stimulating and protective action of human recombinant interleukin-1 beta (betaleukin) in the chemotherapy of malignant tumors].
The investigation was concerned with the leuko-stimulating effect of interleukin-1 beta injected subcutaneously (4.6 +/- 0.3 ng/kg body), daily, for 10 days, to treat toxic leukopenia and neutropenia stage III in cancer patients. Complete recovery of leukocyte levels and granulocytic count (during an average of 9 +/- 1 days) was registered within a period similar to that of intravenous dropwise injection of a single dose of 10-20 ng/kg body. Distinct protective effect on leukopoiesis was achieved following subcutaneous injection of II-1 beta (4.3 +/- 0.2 ng/kg body) in patients with basic leukopenia stage II and neutropenia stage I carried out in conjunction with combination chemotherapy. Due to side effect cytostatic drug administration could be continued.
Filatova
L V
LV
N. N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Gershanovich
M L
ML
Ketlinskiĭ
S A
SA
Simbirtsev
A S
AS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007375:Interleukin-1 / Q000008:administration & dosage*; D019891:Leukopoiesis / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D013268:Stimulation, Chemical
D000970:Antineoplastic Agents; D007375:Interleukin-1; D011994:Recombinant Proteins